Literature DB >> 18335170

Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT.

Y Sai1, T Nishimura, S Shimpo, T Chishu, K Sato, N Kose, T Terasaki, C Mukai, S Kitagaki, N Miyakoshi, Y-S Kang, E Nakashima.   

Abstract

PURPOSE: To characterize the uptake mechanism of zidovudine (AZT), a nucleoside reverse transcriptase inhibitor, in syncytiotrophoblast cells using the TR-TBT 18d-1 cell line previously established by our group.
MATERIALS AND METHODS: The effects of several transporter inhibitors on the initial and steady-state apical uptake of AZT by TR-TBT 18d-1 were characterized, in order to identify the transporter(s) involved.
RESULTS: Initial uptake of AZT was sodium-independent and saturable; the K(m) value was about 16 microM. Nitrobenzylthioinosine (NBMPR), probenecid and cimetidine each had little effect on the saturable AZT uptake, indicating that well characterized transporters, such as organic anion transporters (OATs and OATPs), organic cation transporters (OCTs) and equilibrative nucleoside transporters (ENTs), are not involved. However, thymidine and 2'-deoxyuridine strongly inhibited AZT uptake. These results suggest that an unidentified nucleoside uptake transporter is responsible for the uptake of AZT. Cyclosporin A, Ko143 and probenecid had little effect on AZT accumulation by TR-TBT 18d-1 cells, suggesting that transporter-mediated efflux of AZT is not substantial.
CONCLUSION: Our results indicate that saturable AZT uptake into TR-TBT 18d-1 is mediated by a so-far-unidentified transporter.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335170     DOI: 10.1007/s11095-008-9564-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization.

Authors:  J Wang; S F Su; M J Dresser; M E Schaner; C B Washington; K M Giacomini
Journal:  Am J Physiol       Date:  1997-12

2.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C.

Authors:  I Tamai; T Nozawa; M Koshida; J Nezu; Y Sai; A Tsuji
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

4.  Polarized glucose transporters and mRNA expression properties in newly developed rat syncytiotrophoblast cell lines, TR-TBTs.

Authors:  Tomohide Kitano; Hisashi Iizasa; Tetsuya Terasaki; Tomoko Asashima; Noriko Matsunaga; Naoki Utoguchi; Yoshiteru Watanabe; Masuo Obinata; Masatsugu Ueda; Emi Nakashima
Journal:  J Cell Physiol       Date:  2002-11       Impact factor: 6.384

5.  Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells.

Authors:  N Morita; H Kusuhara; T Sekine; H Endou; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

6.  Nucleoside transport by perfused human placenta.

Authors:  J Dancis; J Lee; S Mendoza; L Liebes
Journal:  Placenta       Date:  1993 Sep-Oct       Impact factor: 3.481

Review 7.  The equilibrative nucleoside transporter family, SLC29.

Authors:  Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young
Journal:  Pflugers Arch       Date:  2003-06-28       Impact factor: 3.657

8.  Azidothymidine (zidovudine) transport by the human placenta.

Authors:  S Schenker; R F Johnson; T S King; R S Schenken; G I Henderson
Journal:  Am J Med Sci       Date:  1990-01       Impact factor: 2.378

9.  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.

Authors:  M J O'Sullivan; P J Boyer; G B Scott; W P Parks; S Weller; M R Blum; J Balsley; Y J Bryson
Journal:  Am J Obstet Gynecol       Date:  1993-05       Impact factor: 8.661

10.  Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.

Authors:  Y Urakami; M Okuda; S Masuda; H Saito; K I Inui
Journal:  J Pharmacol Exp Ther       Date:  1998-11       Impact factor: 4.030

View more
  2 in total

1.  S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein.

Authors:  Sara Karbanova; Ales Sorf; Lucie Jiraskova; Anezka Lalinska; Zuzana Ptackova; Frantisek Staud; Lukas Cerveny
Journal:  Pharm Res       Date:  2020-02-21       Impact factor: 4.200

2.  Identification of p-glycoprotein and transport mechanism of Paclitaxel in syncytiotrophoblast cells.

Authors:  Na-Young Lee; Ha-Eun Lee; Young-Sook Kang
Journal:  Biomol Ther (Seoul)       Date:  2014-01       Impact factor: 4.634

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.